Cipla gets VAI status for Virgonagar facility

Mumbai: Cipla has announced that the United States Food and Drug Administration (USFDA) has classified the inspection at the Company’s manufacturing facility in Virgonagar, Bengaluru, India as Voluntary Action Indicated (“VAI”).

Medical Dialogues team had earlier reported that the Company had received eight observations from the USFDA for Virgonagar, Bengalur for the inspection conducted between 7th – 13th November, 2024.

Voluntary action indicated means objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.

Read also: Cipla to invest ZAR 900 million in equity share capital of South Africa subsidiary

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in its home markets of India, South Africa, North America, and key regulated and emerging markets. It has strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective, and CNS segments. It has 47 manufacturing sites around the world which produces 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to its 80+ markets.

Read also: Cipla Global Chief Manufacturing Officer Rajeev Kumar Sinha resigns